Substituted piperazinoquinazolones: relationship between selective inhibition of nicotinamide adenine dinucleotide-dependent oxidations and anticonvulsant activity.
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002951:Citrates / Q000378:metabolism; D006885:Hydroxybutyrates / Q000378:metabolism; D066298:In Vitro Techniques; D007523:Isocitrates / Q000378:metabolism; D007656:Ketoglutaric Acids / Q000378:metabolism; D008297:Male; D009243:NAD / Q000037:antagonists & inhibitors*; D010084:Oxidation-Reduction; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D010879:Piperazines / Q000138:chemical synthesis / Q000494:pharmacology; D011773:Pyruvates / Q000378:metabolism; D011799:Quinazolines / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D012640:Seizures / Q000139:chemically induced; D013329:Structure-Activity Relationship; D062367:ortho-Aminobenzoates / Q000494:pharmacology
D000927:Anticonvulsants; D002951:Citrates; D006885:Hydroxybutyrates; D007523:Isocitrates; D007656:Ketoglutaric Acids; D010879:Piperazines; D011773:Pyruvates; D011799:Quinazolines; D062367:ortho-Aminobenzoates; D009243:NAD; D010433:Pentylenetetrazole